CRCDx RAS Mutation Detection Assay Kit
Real-time PCR assay that detects KRAS and NRAS exon 2–4 mutations in FFPE colorectal cancer tissue to help identify patients eligible for RAS wild-type–directed therapy.
Casandra.ai provides a unified ordering experience so you can request this test directly from the performing lab, without changing your workflow.
Ordering is available where Casandra has an active integration with the performing lab. Labs that offer this test can connect with us to enable digital ordering.
About this test
CRCDx RAS Mutation Detection Assay Kit is an FDA-approved, qualitative real-time PCR test that detects 35 KRAS and NRAS exon 2, 3, and 4 mutations in genomic DNA from FFPE colorectal cancer tissue. Run on the QuantStudio Dx instrument with dedicated analysis software, it reports mutation detected or not detected to help determine RAS mutation status and support selection of appropriate therapy.
Where this test fits
| Indication | Biomarker | Biomarker details | Therapy (Select a therapy to open its FDA-approved testing pathway) |
|---|---|---|---|
| Colorectal Cancer (CRC) | KRAS and NRAS | wild-type (absence of mutations in exons 2, 3 and 4) | VECTIBIX |
IVD Manufacturer
EntroGen is a leading biotechnology firm offering end-to-end solutions in molecular diagnostics for oncology and hematology by providing automation, reagents, and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout the entire workflow, EntroGen solutions are designed to be accurate, economical, and scalable.
Order this test
If your organization is connected to Casandra, you can place an electronic order forCRCDx RAS Mutation Detection Assay Kit directly from your existing workflow.
Casandra connects providers, labs, and sponsored programs so that companion diagnostics can be ordered consistently and documented cleanly, regardless of which system you start from.